Extended Data Fig. 10. IL-2(V) does not synergize with PD-1 blockade during chronic LCMV infection.

LCMV chronically infected mice were left untreated, or treated with anti-PD-L1 antibody, anti-PD-L1 plus IL-2 wild-type (IL-2(WT)), or anti-PD-L1 plus IL-2(V) (modified IL-2 with abolished CD25 binding) for 2 weeks. a, Numbers of D^bGP276⁺ CD8⁺ T cells in the indicated tissues of the four groups of mice. b, Numbers of D^bGP33⁺ and D^bGP276⁺ CD8⁺ T cells in blood (per 1× 10⁶ PBMCs) in the four groups. c, Numbers of IFNγ⁺ CD8⁺ T cells in the different groups. Spleen cells were stimulated with pools of LCMV-specific peptides for 5 h and analyzed by intracellular cytokine staining. d, Summary data for the expression of various phenotypic markers on D^bGP33⁺ and D^bGP276⁺ CD8⁺ T cells after the different treatments. Results were pooled from 2–3 experiments with 2–3 mice per group in each experiment. Data are presented as geometric mean and 95% CI (a–c) or mean and SD (d) with p values. Statistical comparisons were performed using Kruskal-Wallis test with Dunn’s multiple comparison test (a-c) or one-way ANOVA with Tukey’s multiple comparison test (d). Untx, untreated.